BIOLARGO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.272 USD | -1.98% |
|
-9.63% | +61.90% |
| May. 14 | Transcript : BioLargo, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
| May. 14 | BioLargo, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 53.79 | 48.94 | 80.74 | - |
| Enterprise Value (EV) 1 | 53.79 | 48.94 | 80.74 | 80.74 |
| P/E ratio | -9.75 x | -8.4 x | -27.2 x | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 4 x | 4.24 x | 3.13 x |
| EV / Revenue | - | 4 x | 4.24 x | 3.13 x |
| EV / EBITDA | - | -10.9 x | -68.1 x | 50.9 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 276,003 | 291,393 | 296,840 | - |
| Reference price 2 | 0.1949 | 0.1680 | 0.2720 | 0.2720 |
| Announcement Date | 3/31/23 | 4/1/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 12.23 | 19.05 | 25.76 |
| EBITDA 1 | - | -4.477 | -1.186 | 1.586 |
| EBIT 1 | - | -4.58 | -1.564 | 1.032 |
| Operating Margin | - | -37.45% | -8.21% | 4% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income 1 | -4.473 | -3.504 | -1.64 | 0.9578 |
| Net margin | - | -28.65% | -8.61% | 3.72% |
| EPS 2 | -0.0200 | -0.0200 | -0.0100 | - |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/31/23 | 4/1/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.672 | 4.37 | 4.76 | 4.634 | 4.89 | 5.123 | - | - |
| EBITDA 1 | -1.491 | -0.997 | -0.727 | -0.3529 | -0.2411 | -0.1377 | - | - |
| EBIT 1 | -1.537 | -1.006 | -0.763 | -0.4427 | -0.3398 | -0.2463 | - | - |
| Operating Margin | -57.52% | -23.02% | -16.03% | -9.55% | -6.95% | -4.81% | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income 1 | -1.2 | -0.729 | -0.41 | -0.4591 | -0.3574 | -0.2652 | - | - |
| Net margin | -44.91% | -16.68% | -8.61% | -9.91% | -7.31% | -5.18% | - | - |
| EPS 2 | -0.0100 | -0.0100 | -0.001000 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/23 | 4/1/24 | 5/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/31/23 | 4/1/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.272
USD
Average target price
0.35
USD
Spread / Average Target
+28.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.90% | 80.74M | |
| +6.02% | 105B | |
| -10.42% | 60.07B | |
| +64.76% | 45.92B | |
| +14.74% | 38.18B | |
| -0.02% | 30.95B | |
| +11.82% | 20.12B | |
| +10.49% | 16.47B | |
| +7.90% | 13.8B | |
| -4.54% | 13.05B |
- Stock Market
- Equities
- BLGO Stock
- Financials BioLargo, Inc.
